Core Viewpoint - The article discusses the imminent adjustment period for the Hong Kong Stock Connect, highlighting the potential inclusion of 31 new stocks, including Jinfang Pharmaceutical, which is expected to meet the entry criteria due to its stable market performance [1][2]. Group 1: Company Performance - Jinfang Pharmaceutical's average market capitalization during the review period is reported at HKD 10.296 billion, exceeding the threshold of HKD 9.242 billion by over HKD 1 billion, indicating a strong likelihood of inclusion in the upcoming adjustment [2]. - The stock experienced significant volatility post-IPO, with a peak increase of 115.79% from the issue price, followed by a decline of 29.31% over a month, reflecting market fluctuations and investor sentiment [3][10]. - After reaching a market cap below HKD 10 billion on October 22, the stock quickly stabilized, avoiding further price bubble risks, aided by its IPO structure which limited short-term selling pressure from retail investors [11]. Group 2: Market Context - The Hong Kong innovative drug sector has seen a substantial rally, with the Hang Seng Healthcare Index rising from a low of 2152.38 points to a high of 4726.41 points, marking a maximum increase of 119.59% over eight months [10]. - Jinfang Pharmaceutical's IPO was highly successful, with a subscription rate of 2662.79 times for the public offering, reflecting strong institutional interest in the KRAS inhibitor sector [10]. - The stock's performance is also influenced by broader market trends, as the Hang Seng Healthcare Index experienced an 11.05% correction in October, impacting investor behavior and contributing to Jinfang's price volatility [10]. Group 3: Technical Analysis - Following a significant drop on October 22, Jinfang Pharmaceutical's stock price rebounded sharply, indicating strong buying interest and a potential shift in market sentiment [4][6]. - The stock has entered a phase of stable horizontal consolidation, with a high concentration of shares held by investors, which reduces the likelihood of significant price fluctuations in the near term [6]. - The average cost of shares held by investors remains around HKD 37, which is significantly above the current market price, further discouraging selling and stabilizing the stock [6].

Group 1: Market Recovery - The Hong Kong IPO market has significantly rebounded since Midea Group's "A+H" listing in September 2024, with a strong recovery trend observed[3] - The probability of newly listed Hong Kong stocks rising on their first day is 62.1%, and the probability of them being up after 30 days is 55.6%[6] - The fundraising amount in the Hong Kong IPO market from January to May 2025 has surged by 709.4% year-on-year, nearing the total for the entire year of 2024[20] Group 2: Driving Factors - The core drivers of the Hong Kong IPO market's resurgence in 2025 include policy incentives, increased market attractiveness, and inherent corporate financing needs[7] - The China Securities Regulatory Commission has introduced five measures to encourage mainland companies to list in Hong Kong, significantly lowering the listing threshold[28] - The Hong Kong market's performance has been strong, with a higher proportion of "new economy" sectors, making it more attractive compared to A-shares[35] Group 3: Investment Strategies - Strategy one focuses on the opportunities presented by leading companies listing in Hong Kong, as A-share companies tend to see significant price increases prior to their Hong Kong listings[8] - Strategy two emphasizes the potential for price increases for companies entering the Hong Kong Stock Connect, particularly in sectors like power equipment and defense[9] - Companies such as Heng Rui Medicine and Ningde Times have shown positive stock performance in A-shares leading up to their Hong Kong listings, indicating a favorable trend[25]